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Background and objective: T-cell acute lymphoblastic leukemia (T-ALL) in children represents
a  high-risk disease. There is a lack of studies assessing the outcome of T-ALL in Hispanic
populations, in which it is a rare malignancy. We report the characteristics and results of
treatment for childhood T-cell ALL in children over 14 years at a Latin American reference
center.
Material and methods: From January 2005 to December 2018, there occurred the analysis
of  twenty patients ≤ 16 years of age from a low-income open population diagnosed at
a  university hospital in Northeast Mexico. Clinical and laboratory characteristics, treat-
ment  regimens and outcomes were assessed by scrutinizing clinical records and electronic
databases. Diagnosis was confirmed by flow cytometry, including positivity for CD-2, 5, 7
and  surface/cytoplasmic CD3. Survival rates were assessed by the Kaplan-Meier method.
Results: There was a male preponderance (70 %), with a 2.3 male-to-female ratio (p = .074), the
median age being 9.5 years. Leucocytes at diagnosis were ≥ 50 × 109/L in 13 (65 %) children,
with  CNS infiltration in 6 (30 %) and organomegaly in 10 (50 %). The five-year overall survival
(OS)  was 44.3 % (95 % CI 41.96–46.62), significantly lower in girls, at 20.8 % (95 % CI 17.32–24.51)
vs.  53.1 % (95 % CI 50.30–55.82), (p = .035) in boys; there was no sex difference in the event-free
survival (EFS) (p = .215). The survival was significantly higher after 2010 (p = .034).
Conclusion: The T-cell ALL was more frequent in boys, had a higher mortality in girls and the
survival has increased over the last decade with improved chemotherapy and supportive
care.Please cite this article in press as: Jaime-Pérez JC, et al. Childhood T-cell acu
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Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive
hematologic malignancy that represents approximately 15 %
and 25 % of the total childhood and adult acute lymphoblas-
tic leukemia (ALL) cases, respectively.1,2 T-ALL is a neoplasm
derived from early T-cell progenitors and is an entity distinctly
different from adult T-cell leukemia/lymphoma, which is a
mature T-cell neoplasm attributed to the human retrovirus
known as human T-cell leukemia virus type I (HTLV-I).3
T-ALL tends to occur in older adolescents with a notably
male predominance. It has been associated with a poorer
prognosis, compared to B-cell ALL (B-ALL), showing inferior
event-free survival (EFS) and overall survival (OS).4 These infe-
rior outcomes are partially explained by the association of the
disease with high-risk clinical features, including older patient
age, hyperleukocytosis with extramedullary involvement and
central nervous system (CNS) infiltration.5,6
Although intensified chemotherapy protocols in high-
income countries have increased the OS to 80 % in children
with T-ALL, these rates still lag behind its B-cell counterpart.4,6
A relapse in ALL is an event that leads to a dismal prognosis
and thus, the T-cell immunophenotype is considered a predic-
tor of inferior post-relapse survival in ALL.7
We  were unable to locate reports specifically dealing with
the childhood T-ALL incidence, clinical presentation, response
to therapy, clinical course and survival rates in the Latin Amer-
ican Hispanic populations. Reports on this group are needed to
enhance our understanding of the disease and improve treat-
ment protocols. The objective of the present report was to
analyze these variables in children belonging to an open pop-
ulation in Northeast Mexico treated at a referral center over
fourteen years.
Methods
This observational, longitudinal and retrospective study
included 20 newly  diagnosed T-ALL patients, aged ≤ 16 years
attending a single referral center in Northeast Mexico. Eligible
patients were those who had complete information in their
clinical files and the electronic databases and who had been
diagnosed and treated between January 2005 and December
2018 at the Hematology Department of an academic referral
center that provides health care for the low-income uninsured
open population. Pertinent clinical and biological variables
were documented. The study protocol was approved by the
Research and Ethics Committee and informed consent was
waived.
Diagnosis  and  relapse  criteria
In addition to a complete medical history and physical exami-
nation, the diagnosis of T-ALL, as the first primary malignancy,Please cite this article in press as: Jaime-Pérez JC, et al. Childhood T-cell acu
of improved treatment scheme and support therapy on survival. Hematol
required a combination of morphology, immunophenotyping
and cytogenetic analysis.2 Immunophenotyping was per-
formed by flow cytometry, including positivity for CD-2, 5, 7
and surface/cytoplasmic CD3. Owing to financial restrictions,2 0 1 9;x x x(x  x):xxx–xxx
cytogenetic studies were performed in a minority of patients
and thus, were not included.
Lumbar puncture was performed at diagnosis, with CNS
infiltration defined as > 5 leukocytes/mm3 with blast mor-
phology in the cerebrospinal fluid. Relapse was defined as
the reemergence of the disease and classified as bone mar-
row, combined or extramedullary. Overall survival was defined
as the time from date of diagnosis to death from any cause.
Event-free survival was defined as the time from date of diag-
nosis to the first event of relapse or death. Fluorescence in situ
hybridization and polymerase chain reaction (PCR) were used
to assess Philadelphia (Ph) chromosome status; flow cytom-
etry minimal residual disease (MRD) studies were performed
at the end of induction on day 29 and MRD  was considered
present if > 0.01 %. Response to steroids was determined
using the absolute count of blasts in peripheral blood on
day 8 after 7 days of steroid administration. Complete mor-
phological remission was defined as the presence of < 5 %
lymphoblasts in bone marrow (BM) on day 36. Organomegaly
and lymphadenopathy were documented by clinical examina-
tion at the time of diagnosis.
Treatment
The children were stratified into standard and high-risk
groups according to the National Cancer Institute/Rome
risk criteria to receive risk-adapted chemotherapy.8,9 Briefly,
for children ≤ 16 years during the 2005–2009 period, a
protocol based on the LSA2L2 was administered. Induc-
tion included standard doses of cyclophosphamide (Cy)
prednisone (PDN), vincristine (VCR), adriamycin (ADR) and
intrathecal chemotherapy. Consolidation included methotrex-
ate (MTX), cytosine arabinoside (Ara-C) and purinethol
(6 M P).10 From 2010 onwards, a BFM-based-scheme was
administered. Induction consisted of l-asparaginase, PDN,
VCR and ADR. Consolidation included MTX, Ara-C and 6 M P.11
Before 2010, support therapy was limited due to financial
restrictions at our hospital, including restricted antibiotic and
antifungal choices, as well as the unavailability of apheresis
platelets.
Statistical  analysis
Statistical analyses were performed using the IBM SPSS Statis-
tical software for Windows, Version 22.0 (IBM Corp., Armonk,
NY). Since data were nonparametric, descriptive statistics
results for continuous variables are presented as medians
and ranges. Categorical variables are displayed as absolute
numbers and percentages. Demographic and clinical char-
acteristics were compared, using the 2 test for categorical
variables and the Mann–Whitney U test for quantitative
variables. Overall survival and EFS were estimated by the
Kaplan-Meier method and groups were compared with the
log-rank test. The Cox proportional hazard regression model
with 95 % confidence intervals (CI) was used for uni- and mul-te lymphoblastic leukemia in a single Latin American center: impact
 Transfus Cell Ther. 2019. https://doi.org/10.1016/j.htct.2019.09.005
tivariate analysis. The significance level was set at p < 0.05 for
all analyses.
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Table 1 – Clinical and laboratory characteristics of
twenty children with T-cell acute lymphoblastic
leukemia (T-ALL), aged ≤ 16 years, treated at a referral
center in Mexico.
Characteristics N (%)
Age, median (years), range 9.5 (2–16)
Sex
Male 14 (70)
Female 6 (30)
WBC × 109/L
≥ 50a 13 (65)
< 50 7 (35)
Initial CNS involvement
Present 6 (30)
Absent 14 (70)
Mediastinal mass
Yes 4 (20)
No 16 (80)
Adenopathy
Yes 8 (40)
No 12 (60)
Organomegaly
Yes 10 (50)
No 10 (50)
MRD
Positive 4 (20)
Negative 16 (80)
Abbreviations: CNS, central nervous system; MRD, minimal residual
disease; WBC,white blood cells.
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Table 2 – Characteristics and statistical comparison (x2)
of 20 patients with T-cell acute lymphoblastic leukemia
(T-ALL) in Northeast Mexico between 2005 and 2018.
Characteristic < 2010, n (%) ≥ 2010 n, (%) pa
Total 8  (40) 12 (60) .371
Median age, years (range) 5 (2–14) 11 (2–16) .650
Sex
Male 5 (62.5) 9 (75) .550
Female 3 (37.5) 3 (25) –
WBC × 109/L
≥ 50 4 (50) 9 (75) .251
< 50b 4 (50) 3 (25)
Initial CNS involvement
Yes 1 (12.5) 5 (41.7) .163
No 7 (87.5) 7 (58.3)
Mediastinal mass
Yes 1 (12.5) 3 (25) .494
No 7 (87.5) 9 (75)
Adenopathy
Yes 2 (25) 6 (50) .264
No 6 (75) 6 (50)
Organomegaly
Yes 5 (62.5) 5 (41.7) .361
No 3 (37.5) 7 (58.3)
MRD
Positive 2 (25) 2 (16.7) .648
Negative 6 (75) 10 (83.3)
Abbreviations: CNS, central nervous system; WBC, white blood
cells.
a Mann-Whitney U test for age, 2 for all other variables.a WBC cutoff value was 50,000/L.
esults
atient  population
he study group included 20 patients, representing 5.7 % of
49 ALL cases diagnosed during the study period; there was
 male preponderance with 14 males (70 %) vs. 6 females
30 %) (p = .074), with a male-to-female ratio of 2.3. For the
hole group, the median age at diagnosis was 9.5 years (2–16);
edian age for females was 6.5 years (2–14) vs. 10.5 years (2–16)
or males (p = 0.628). The patient characteristics are shown in
able 1. The median follow-up was 27 months (2–122).
utcomes
or the whole group, the OS at 5 years was 44.3 % (95 % CI
1.96–46.62), whereas the EFS was 41.5 % (95 % CI 39.22–43.76).
he 5-year OS significantly varied by sex; for males, it reached
3.1 % (95 % CI 50.30–55.82) vs. 20.8 % for females (95 % CI
7.32–24.51) (p = .035) (Figure 1). For males, the 5-year EFS was
8.2 % (95 % CI 45.47–55.88) and for females, 25 % (95 % CI
1.10–29.08) (p = .215). The five-year OS and EFS did not sig-
ificantly differ between age groups; for those aged 1–9 years,
he OS was 33.3 % (95 % CI 30.24–36.39) vs. 58.3 % (95 % CI
5.07–61.38) (p = .609) in patients > 9 years, whereas the EFS
ates were 35 % (CI 31.88–38.14) and 48 % (CI 44.75–51.17) (p =Please cite this article in press as: Jaime-Pérez JC, et al. Childhood T-cell acu
of improved treatment scheme and support therapy on survival. Hematol
572), respectively.
The cohort was divided into two groups based on the date
f diagnosis and treatment protocol administered, before andb WBC cutoff value was 50,000/L.
after 2010. Characteristics of these groups are presented in
Table 2. Over time, the five-year OS improved significantly
(Figure 2A). For children diagnosed before 2010, it was 12.5
% (CI 10.32–14.90), compared to 72.2 % (CI 69.39–74.80) (p =
.034) for patients treated from 2010 onwards; in the same
period, the five-year EFS was 12.5 % (CI 10.32–14.90) vs. 64.8
(CI 61.92–67.52) (p = .074) (Figure 2B). There were no significant
differences in the 5-year OS and EFS when patients with ini-
tial organomegaly, adenopathy, CNS infiltration, and positive
MRD were compared with those lacking these characteristics
(data not shown).
Complete  remission  (CR)
Eighteen (90 %) patients reached complete CR. Two (10 %) of
the 20 patients failed to achieve CR, 1 died during induction
and 1 had a transplant without remission.
Hematopoietic  stem  cell  transplant  (HSCT)
Five (25 %) children received a HSCT, two while in relapse, one
in partial and two in complete remission. The HLA-identical
(n = 2) and haploidentical (n = 3) transplants were performed.
Three patients died due to septic shock (n = 1), gastrointesti-
nal bleeding (n = 1) or pulmonary edema (n = 1). The mediante lymphoblastic leukemia in a single Latin American center: impact
 Transfus Cell Ther. 2019. https://doi.org/10.1016/j.htct.2019.09.005
follow-up after the HSCT was 19 months (2–22).
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Figure 1 – A. Fourteen male children with T-cell acute lymphoblastic leukemia had a five-year overall survival, significantly
higher than that of six females, treated at a Latin American center. B. The five-year event-free survival was not statistically
different.
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Figure 2 – A. The five-year overall survival for 12 children diagnosed with T-cell acute lymphoblastic leukemia after 2010
was significantly higher than in those treated before this year. B. The five-year EFS between the two periods did not reach a
hose
Discussion
Although higher incidence rates of ALL have been reported
in Latin American countries, the majority arise fromstatistical difference, however, it was clinically superior for t
Relapse
A total of 10 (50 %) patients relapsed, 5 out of 8 (62.5 %) before
2010 and 5 out of 12 (41.6 %) after that year. Relapse occurred
at a median of 7.5 months (2–73), with the majority (n = 8, 80
%) of relapses occurring within the first year after diagnosis.
Relapsed patients had a 5-year OS of 20 % (CI 95 % 17.59–22.52)
vs. 75 % (CI 95 % 72.43–77.37) in patients who did not relapse.
(p = .007).
In the whole group, the BM was the main site of relapse;
isolated BM relapse (n = 5) was followed by combined BM and
CNS (n = 3), isolated CNS (n = 1), and BM and testicular relapse
(n = 1). Two children who suffered a relapse in the CNS, one
isolated and one combined with the BM,  had a CNS infiltration
at diagnosis.Please cite this article in press as: Jaime-Pérez JC, et al. Childhood T-cell acu
of improved treatment scheme and support therapy on survival. Hematol treated from 2010 onwards.
Causes  of  death
Ten deaths (50 %) were documented, seven of which before
2010. The main cause was sepsis in four patients (57 %), gas-
trointestinal bleeding and pulmonary edema in one each,
while in one case, further treatment was rejected; after 2010,
three children died, the causes being sepsis, acute respiratory
failure, and gastrointestinal bleeding. Two patients who  died
were in remission and eight in relapse.te lymphoblastic leukemia in a single Latin American center: impact
 Transfus Cell Ther. 2019. https://doi.org/10.1016/j.htct.2019.09.005
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-lymphoblasts and a small subset, from T-lymphoblasts.12–15
he proportion of T-ALL is lower than the 15.2 % reported
n the United States.16 The incidence of T-ALL in our pop-
lation has been reported at 5 % in children and 8 % in
dults,17 in contrast with 10–15% and 25 %, respectively, found
n other groups.5,18 Our 5.7 % T-ALL proportion is less than
he 12.4 % reported in Mexico City14 and half the 10–11 %
eported in other Latin American countries.19–21The lower
ncidence of T-ALL in our study seems to confirm the geo-
raphic variation in the biologic subtype expression due to
enetic heterogeneity and diversity according to the ethnic
omposition.22,23
T-ALL is characterized by a sex distribution favoring males.
n our cohort, the male-to-female ratio was 2.3, close to the
.2 and 3.0 ratios reported in other studies.16,24 The sex distri-
ution ratio is more  striking than its B-cell counterpart, which
as been reported at around 1.2 in the United States and Latin
merican countries.16,17 There are studies suggesting the role
f specific mutations to explain the male predominance, such
s the UTX, which is a sex-specific tumor suppressor protein.
4
Similar to other pediatric T-ALL studies, the median age at
iagnosis was 9 years, older than that reported for B-ALL.17,25
oreover, the females were younger.26 The variation in age
etween sexes in T-ALL has not been studied in depth, as most
pidemiology reports on ALL combine B-ALL and T-ALL data.
mportantly, 30 % of our patients had CNS infiltration at diag-
osis, compared to 7 % in recent reports.6 This increase in
NS disease can be due to delayed diagnosis, differences in
eukemic clone activity, or both.
Remarkably, the OS rate in girls was significantly lower,
ontrasting with other T-ALL reports, in which boys have a
rimmer prognosis.27 In contrast, there was no significant dif-
erence in respect to the EFS; this could probably be due to the
mall study sample. Relapsed T-ALL patients have a dismal
utcome; in our cohort most relapses occurred within the first
ear after diagnosis with a low OS rate of 20 % at 5 years, sim-
lar to what has been documented7 and half the 42 % reached
or B-cell ALL relapsed children in our own population.28
mportantly, the OS and EFS significantly improved after 2010,
eaching 72.2 % and 64.8 %, respectively, not being that far
rom the 80 % and 75 %, respectively, reported in high-income
ountries.4 This was most probably a consequence of bet-
er treatment and supportive therapy, including opportune
dministration of prophylactic, as well as therapeutic, antibi-
tics and antifungals, coupled with on-demand transfusion
upport with apheresis platelets; platelet support positively
nfluenced outcomes, but before 2010 platelet apheresis for
ematology patients was restricted at our public institution
ue to financial limitations, whereas after this year, it became
ermanently available. Importantly, regular platelet concen-
rates at our center are limited due to the reduced percentage
f volunteer blood donors, at 2.38 %, compared to 63.62 % in
razil.29
The improvements in the study period were financed by a
ederal government program, the “Seguro Popular” (People’sPlease cite this article in press as: Jaime-Pérez JC, et al. Childhood T-cell acu
of improved treatment scheme and support therapy on survival. Hematol
nsurance), that allocates funds for childhood leukemia treat-
ent, as we have previously reported, for the hospitalization
f children with ALL.30
1 0 1 9;x  x x(x x):xxx–xxx 5
The main study limitations include, but are not limited to,
the single-center setting and the relatively small sample size.
In conclusion, in our Latin American Hispanic group, the
T-cell ALL was a rare leukemia, more  frequent in boys, with
a worst prognosis in girls, and a high frequency of CNS infil-
tration; after 2010, intensified chemotherapy, improved blood
products support and adequate infection prophylaxis resulted
in significantly greater survival rates, approaching those in
high-income countries.
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